- Home
- MG vs TSHA Comparison
MG vs TSHA Comparison
Compare MG & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MG
- TSHA
- Stock Information
- Founded
- MG 1978
- TSHA 2019
- Country
- MG United States
- TSHA United States
- Employees
- MG N/A
- TSHA N/A
- Industry
- MG Military/Government/Technical
- TSHA Biotechnology: Pharmaceutical Preparations
- Sector
- MG Consumer Discretionary
- TSHA Health Care
- Exchange
- MG Nasdaq
- TSHA Nasdaq
- Market Cap
- MG 303.0M
- TSHA 334.1M
- IPO Year
- MG 2009
- TSHA 2020
- Fundamental
- Price
- MG $9.88
- TSHA $1.74
- Analyst Decision
- MG Hold
- TSHA Strong Buy
- Analyst Count
- MG 1
- TSHA 8
- Target Price
- MG $11.00
- TSHA $6.63
- AVG Volume (30 Days)
- MG 139.0K
- TSHA 1.5M
- Earning Date
- MG 03-05-2025
- TSHA 02-26-2025
- Dividend Yield
- MG N/A
- TSHA N/A
- EPS Growth
- MG N/A
- TSHA N/A
- EPS
- MG 0.60
- TSHA N/A
- Revenue
- MG $729,640,000.00
- TSHA $8,333,000.00
- Revenue This Year
- MG $5.79
- TSHA N/A
- Revenue Next Year
- MG $3.26
- TSHA N/A
- P/E Ratio
- MG $16.45
- TSHA N/A
- Revenue Growth
- MG 3.43
- TSHA N/A
- 52 Week Low
- MG $7.45
- TSHA $1.19
- 52 Week High
- MG $12.44
- TSHA $4.32
- Technical
- Relative Strength Index (RSI)
- MG 50.08
- TSHA 54.79
- Support Level
- MG $9.75
- TSHA $1.69
- Resistance Level
- MG $10.45
- TSHA $1.82
- Average True Range (ATR)
- MG 0.43
- TSHA 0.10
- MACD
- MG -0.00
- TSHA 0.01
- Stochastic Oscillator
- MG 49.44
- TSHA 68.00
About MG Mistras Group Inc
MISTRAS Group Inc provides asset protection solutions and systems. The company evaluates the structural integrity and reliability of critical energy, industrial, and public infrastructure. The company's three operating segments are North America, International and Products and Systems, of which key revenue is derived from the North America segment. Services segment provides asset protection solutions predominantly in North America, with the large amount of concentration in the United States, followed by Canada, consisting of non-destructive testing, and inspection. The asset protection solutions include field inspections, consulting, maintenance, data management, access, monitoring and laboratory quality assurance.
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.